Design of novel bioisosteres of β-diketo acid inhibitors of HIV-1 integrase

Antiviral Chemistry and Chemotherapy

Volumn 16, Issue 1, 2005, Pages 41-61

  Sechi, Mario ^a   Sannia, Luciano ^a   Carta, Fabrizio ^a   Palomba, Michele ^a   Dallocchio, Roberto ^b   Dessì, Alessandro ^b   Derudas, Massimiliano ^a   Zawahir, Zahrah ^c   Neamati, Nouri ^c  

^a UNIVERSITY OF SASSARI   (Italy)

^b CNR Consiglio Nazionale delle Ricerche   (Italy)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

3D database; Bioisosterism; Drug discovery; High throughput docking; HIV 1 integrase inhibitors; Isoxazole carboxylic acids; Lead compounds

Indexed keywords

1 (5 CHLOROINDOL 3 YL) 3 HYDROXY 3 (2H TETRAZOL 5 YL)PROPENONE; 1 [5 (4 FLUOROBENZYL) 2 FURYL] 3 (1,2,4 TRIAZOL 3 YL) 1,3 PROPANEDIONE; 4 [1 (4 FLUOROBENZYL) 2 PYRROLYL] 2,4 DIOXOBUTYRIC ACID; CARBOXYLIC ACID DERIVATIVE; DFC 28; DFC 7; INTEGRASE INHIBITOR; ISOXAZOLE 3 CARBOXYLIC ACID; ISOXAZOLE DERIVATIVE; L 708906; N (4 FLUOROBENZYL) 8 HYDROXY 5 (TETRAHYDRO 2H 1,2 THIAZIN 2 YL) 1,6 NAPHTHYRIDINE 7 CARBOXAMIDE S,S DIOXIDE; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; INTEGRASE; OXOACID;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CLAISEN CONDENSATION; DRUG DESIGN; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVE SITE; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR MODEL; NONHUMAN; NUCLEAR OVERHAUSER EFFECT; PHARMACOPHORE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION; STRUCTURE ACTIVITY RELATION; VIRUS DNA CELL DNA INTERACTION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; SYNTHESIS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; KETO ACIDS; MODELS, MOLECULAR;

EID: 17144362894     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020501600105     Document Type: Article

References (83)

1. 13C chemical shifts using ab initio model calculations. Analysis of the observed isotope effects on sterically perturbed intramolecular hydrogen-bonded o-hydroxy acyl aromatics. Journal of the American Chemical Society 120:9063-9069.
2. Adam W, Fell R & Shulz MH (1993) Synthesis and fluoride ion-triggered chemiluminescence (CIEEL mechanism) of siloxy-substituted benzofuran dioxeatanes. Tetrahedron 49:2227-2238.
3. Anthony NJ (2004) HIV-1 integrase: a target for new AIDS chemotherapeutics. Current Topics in Medicinal Chemistry 4:979-990.
4. Asante-Appiah E & Skalka AM (1997) Molecular mechanism in retrovirus DNA integration. Antiviral Research 36:139-156.
5. Asante-Appiah E St Skalka AM (1999) HIV-1 integrase: structural organization, conformational changes, and catalysis. Advances in Virus Research 52:351-369.
6. Asante-Appiah E, Merkel G & Skalka AM (1998) Purification of untagged retroviral integrases by immobilized metal ion affinity chromatography. Protein Expression & Purification 12:105-110.
7. Autrey RL & Tahk FC (1967) The synthesis and stereochemistry of some isatylideneacetic acid derivatives. Tetrahedron 23:901-917.
8. Barreca ML, Lee KW, Chimirri A & Briggs JM (2003) Molecular dynamics studies of the wild-type and double mutant HIV-1 integrase complexed with the 5CITEP inhibitor: mechanism for inhibition and drug resistance. Biophysical Journal 8:1450-1463.
9. Battaglia A, Dondoni A & Taddei F (1970) Isoxazoles from nitrile oxides and acetylenes. Substituent effect on the pmr spectra of disubstituted isoxazoles. Journal of Heterocyclic Chemistry 7:721-724.
10. Baumstark AL, Chrisope DR, Keel RA & Boykin DW (1980) A carbon-13 nmr assignment study of 3,5-diarylisoxazoles. Journal Heterocyclic Chemistry 17:1719-1721.
11. Billich A (2003) S-1360 Shionogi-GlaxoSmithKline. Current Opinion in Investigational Drugs 4:206-209.
12. Brown PO (1998) In Retroviruses. Edited by JM Coffin, SH Hughes and HE Varmus. Cold Spring Harbor: Cold Spring Harbor Press, pp. 161-203.
13. Buolamwini JK & Assefa H (2002) CoMFA and CoMSIA 3D docking studies on conformationally-restrained cinnamoyl HIV-1 integrase inhibitors: exploration of a binding mode at the active site. Journal of Medicinal Chemistry 45:841-852.
14. Bushman FD & Craigie R (1991) Activities of human immunodeficiency virus (HIV) integration protein in vitro: specific cleavage and integration of HIV DNA. Proceedings of the National Academy of Sciences, USA 88:1339-1343.
15. Chang G, Guida WC & Still WC (1989) An internal coordinate Monte Carlo method for searching conformational space. Journal of the American Chemical Society 111:4379-4386.
16. Chen I-J, Neamati N & MacKerrel A (2002) Structure-based inhibitor design targeting HIV-1 integrase. Current Drug Targets - Infectious Disorders 2:217-234.
17. Chen I-J, Neamati N, Nicklaus MC, Orr A, Anderson L, Barchi JJ Jr, Kelley JA, Pommier Y & MacKerrel AD Jr (2000) Identification of HIV-1 integrase inhibitors via three-dimensional database searching using ASV and HIV-1 integrases as targets. Bioorganic & Medicinal Chemistry 8:2385-2398.
18. Chiu TK & Davies DR (2004) Structure and function of HIV-1 integrase. Current Topics in Medicinal Chemistry 4:965-977.
19. Chupp JP & Olin JF (1967) Chemical and physical properties of some rotational isomers of α-haloacetanilides. A novel unreactive halogen system. Journal of the Chemical Society - Perkin Transactions 1:2297-2303.
20. D'Angelo J, Mouscadet JF, Desmaele D, Zouhiri F & Leh H (2001) HIV-1 integrase: the next target for AIDS therapy? Pathologie Biologie 49:237-246.
21. Dayam R & Neamati N (2003) Small-molecule HIV-1 integrase inhibitors: the 2001-2002 update. Current in Pharmaceutical Design 9:1789-1802.
22. De Clercq E (2000) Current lead natural products for the chemotherapy of human immunodeficiency virus (HIV) infection. Medicinal Research Reviews 20:323-349.
23. Ellison V & Brown PO (1994) A stable complex between integrase and viral DNA ends mediates human immunodeficiency virus integration in vitro. Proceedings of the National Academy of Sciences, USA 91:7316-7320.
24. Emerson DW, Titus RL & Gonzāles RM (1991) Evidence for ketene intermediates in the decarbonylation of 2,4-dioxo acids and esters and 2-oxobutanedioc acid esters. Journal of Organic Chemistry 56:5301-5307.
25. Garrido DOA, Buldain G & Frydman B (1984) 1,4-Diaminoalkanes from pyrroles. A new synthetic approach to subtituted putrescines. Journal of Organic Chemistry 49:2619-2622.
26. Gasteiger J & Marsili M (1980) Iterative partial equalization of orbital electronegativity - a rapid access to atomic charges. Tetrahedron 36:3219-3228.
27. Goldgur Y, Craigie R, Cohen GH, Fujiwara T, Yoshinaga T, Fujishita T, Sugimoto H, Endo T, Murai H & Davies DR (1999) Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. Proceedings of the National Academy of Sciences, USA 96:13040-13043.
28. Grobler JA, Stillmock K, Hu B, Witmer M, Felock P, Espeseth AS, Wolfe A, Egbertson M, Bourgeois M, Melamed J, Wai JS, Young S, Vacca J & Hazuda DJ (2002) Diketo acid inhibitor mechanism and HIV-1 integrase: implication for metal binding in the active site of phosphotranferase enzymes. Proceedings of the National Academy of Sciences, USA 99:6661-6666.
29. Hazuda DJ, Anthony NJ, Gomez RP, Jolly SM, Wai JS, Zhuang L, Fisher TE, Embrey M, Guare JP Jr, Egbertson MS, Vacca JP, Huff JR, Felock PJ, Witmer MV, Stillmock KA, Danovich R, Grobler J, Miller MD, Espeseth AS, Jin L, Chen IW, Lin JH, Kassahun K, Ellis JD, Wong BK, Xu W, Pearson PG, Schleif WA, Cortese R, Emini E, Summa V, Holloway MK & Young SD (2004) A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proceedings of the National Academy of Sciences, USA 101:11233-11238.
30. Hazuda DJ, Felock PJ, Hastings JC, Pramanick B & Wolfe AL (1997) Differential divalent cation requirements uncouple the assembly and catalityc reactions of human immunodeficiency virus type 1 integrase. Journal of Virology 71:7005-7011.
31. Hazuda DJ, Felock PJ, Witmer M, Wolfe A, Stillmock K, Grobler JA, Espeseth A, Gabryelski L, Schleif W, Blau C & Miller MD (2000) Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 287:646-650.
32. Hennessy EJ & Buchwald SL (2003) Synthesis of substituted oxindoles from α-chloroacetanilides via palladium-catalyzed C-H functionalization. Journal ot the American Chemical Society 125:12084-12085.
33. Hong H, Neamati N, Wang S, Nicklaus MC, Mazumder A, Zhao H, Burke TR Jr, Pommier Y & Milne GWA (1997) Discovery of HIV-1 integrase inhibitors by pharmacophore searching. Journal of Medicinal Chemistry 40:930-936.
34. Hong H, Neamati N, Winslow HE, Christensen JL, Orr A, Pommier Y & Milne GW (1998) Identification of HIV-1 integrase inhibitors based on a four-point pharmacophore. Antiviral Chemistry & Chemotherapy 6:461-472.
35. House HO, Larson JK & Mueller HC (1968) Perhydroindan derivatives. X. The Diels-Alder reaction with 6-methoxyindene derivatives. Journal of Organic Chemistry 33:961-968.
36. Jahangir, Brook MA, Maclean DB & Holland HL (1987) A new route to the indolopyridonaphthyridine ring system: synthesis of N-benzyl-13b,14- dihydronauclefine and N-benzyl-13b,14-dihydroangustine. Tetrahedron 43:5761-5768.
37. Johnson AA, Marchand C & Pommier Y (2004) HIV-1 integrase inhibitors: a decade of research and two drugs in clinical trial. Current Topics in Medicinal Chemistry 4:1059-1077.
38. Katritzky AR & Akutagawa K (1985) Carbon dioxide: a reagent for the protection of nucleophilic centres and the simultaneous activation of alternative locations to electrophilic attack. Part I. A new synthetic method for the 2-substitution of 1-unsubstituted indoles. Tetrahedron Letters 26:5935-5938.
39. Kees KL, Caggiano TJ, Steiner KE, Fitzgerald JJ, Kates MJ, Christos TE, Kulishoff JM, Moore RD & McCaleb ML (1995) Studies on new acidic azoles as glucose-lowering agents in obese, diabetic db/db mice. Journal of Medicinal Chemistry 38:617-628.
40. King GS, Magnus PD & Rzepa HS (1972) Reductive and oxidative cleavage. Journal of the Chemical Society- Perkin Transactions 1:437-443.
41. Kraus GA, Fulton BS & Hyung Woo S (1984) Aliphatic acyl transfer in the Baker-Venkataraman reaction. Journal of Organic Chemistry 49:3212-3214.
42. Kulkosky J, Jones KS, Katz RA, Mack JP & Skalka AM (1992) Residues critical for retroviral integrative recombination in a region that is highly conserved among retroviral/retrotransposon integrases and bacterial insertion sequence transposases. Molecular & Cellular Biology 12:2331-2338.
43. Lipinski CA (1986) Bioisosterism in drug design. In Annual Reports in Medicinal Chemistry, vol. 2. Edited by C Allen. London: Academic Press, pp. 283-291.
44. Long DR, Richards CD & Ross MSF (1978) The stereochemistry of 2-oxoindolin-3-ylidene derivatives. Journal of Heterocyclic Chemistry 15:633-636.
45. Long YO, Jiang XH, Dayam R, Sanchez T, Shoemaker R, Sei S St Neamati N (2004) Rational design and synthesis of novel dimeric diketoacid-containing inhibitors of HIV-1 integrase: implication for binding to two metal ions on the active site of integrase. Journal of Medicinal Chemistry 47:2561-2573.
46. Makhija MT, Kasliwal RT, Kulkarni VM & Neamati N (2004) De novo design and synthesis of HIV-1 integrase inhibitors. Bioorganic & Medicinal Chemistry 12:2317-2333.
47. Marchand C, Johnson AA, Karki RG, Pais GC, Zhang X, Cowansage K, Patel TA, Nicklaus MC, Burke TR Jr & Pommier Y (2003) Metal-dependent inhibition of HIV-1 integrase by beta-diketo acids and resistance of the soluble double-mutant (F185K/C280S). Molecular Pharmacology 64:600-609.
48. Maurin C, Bailly F & Cotelle P (2003) Structure-activity relationships of HIV-1 integrase inhibitors-enzyme-ligand interactions. Current Medicinal Chemistry 10:1795-1810.
49. Melek M, Jones JM, O'Dea MH, Pais G, Burke TR Jr, Pommier Y, Neamati N & Gellert M (2002) Effect of HIV integrase inhibitors on the RAG1/2 recombinase. Proceedings of the National Academy of Sciences, USA 99:134-137.
50. Milne GWA, Nicklaus MC, Driscoll JS & Wang S (1994) National Cancer Institute drug information system 3D database. Journal of Chemical Information & Computer Sciences 34:1219-1224.
51. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK & Olson AJ (1998) Automated docking using a Lamarckian genetic algorithm an empirical binding free energy function. Journal of Computational Chemistry 19:163-166.
52. Morris GM, Goodsell DS, Huey R & Olson A (1996) Distributed automated docking of flexible ligands to proteins: Parallel application of AutoDock 2.4*. Journal of Computational-Aided Molecular Design 10:293-304.
53. Neamati N (2001) Structure-based HIV-1 integrase inhibitor design: a future perspective. Expert Opinion on Investigational Drugs 10:281-296.
54. Neamati N (2002) Patented small molecule inhibitors of HIV-1 integrase: a ten-year saga. Expert Opinion on Therapeutic Patents 12:709-724.
55. Neamati N & Barchi JJ Jr (2002) New paradigms in drug design and discovery. Current Topics in Medicinal Chemistry 2:211-227.
56. Neamati N, Hong H, Mazumder A, Wang S, Sunder S, Nicklaus MC, Milne GWA, Proska B & Pommier Y (1997) Depsides and Depsidones as inhibitors of HIV-1 Integrase: Discovery of novel inhibitors through 3D database searching. Journal of Medicinal Chemistry 40:942-951.
57. Neamati N, Hong H, Owen JM, Sunder S, Winslow HE, Christensen JL, Zhao H, Burke TR Jr, Milne GW & Pommier Y (1998) Salicylhydrazine-containing inhibitors of HIV-1 integrase: implication for a selective chelation in the integrase active site. Journal of Medicinal Chemistry 41:3202-3209.
58. Neamati N, Hong H, Sunder S, Milne GW & Pommier Y (1997) Potent inhibitors of human immunodeficiency virus type-1 integrase: identification of a novel four-point pharmacophore and tetracyclines as novel inhibitors. Molecular Pharmacology 52:1041-1055.
59. Neamati N, Lin Z, Karki RG, Orr A, Cowansage K, Strumberg D, Pais GC, Voigt JH, Nicklaus MC, Winslow HE, Zhao H, Turpin JA, Yi J, Skalka AM, Burke TR Jr & Pommier Y (2002) Metal-dependent inhibition of HIV-1 integrase. Journal of Medicinal Chemistry 45:5661-5670.
60. Neamati N, Marchand C & Pommier Y (2000) HIV-1 integrase inhibitors: past, present, and future. In Advances in Pharmacology, vol. 49. San Diego: Academic Press, pp. 147-165.
61. Neamati N, Marchand C, Winslow HE & Pommier Y (2001) Human immunodeficiency virus type 1 integrase-targeted inhibitor design. Antiretroviral Therapy 5:87-104.
62. Ni H, Sotriffer CA & McCammon JA (2001) Ordered water and ligand mobility in the HIV-1 integrase-5CITEP complex: a molecular dinamics study. Journal of Medicinal Chemistry 44:3043-3047.
63. Nicklaus MC, Neamati N, Hong H, Mazumder A, Sunder S, Chen J, Milne GWA & Pommier Y (1997) HIV-1 integrase pharmacophore: discovery of inhibitors through three-dimensional database searching. Journal of Medicinal Chemistry 40:920-929.
64. Ouali M, Laboulais C, Leh H, Gill D, Xhuvani E, Zouhiri F, Desmaele D, d'Angelo J, Auclair C & Mouscadet JF (2000) Tautomers of styrylquinoline derivatives containing a methoxy substituent: computation of their population in aqueous solution and their interaction with RSV integrase catalytic core. Acta Biochimica Polonica 47:11-22.
65. Pais GCG & Burke TR Jr (2002) Novel aryl diketo-containig inhibitors of HIV-1 integrase. Drugs of the Future 27:1101-1111.
66. Pais GC, Zhang X, Marchand C, Neamati N, Cowansage K, Svarovskaia ES, Pathak VK, Tang Y, Nicklaus M, Pommier Y & Burke TR Jr (2002) Structure activity of 3-aryl-1,3-diketo-containing compounds as HIV-1 integrase inhibitors. Journal of Medicinal Chemistry 45:3184-3194.
67. Parril AL (2003) HIV-1 integrase inhibition: binding sites, structure activity relationships and future perspectives. Current Medicinal Chemistry 10:1875-1888.
68. Patani GA & La Voie E (1996) Bioisosterism: a rational approach in drug design. Chemical Reviews 96:3147-3176.
69. Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S, Graneto MJ, Lee LF, Malecha JW, Miyashiro JM, Rogers RS, Rogier DJ, Yu SS, Anderson GD, Burton EG, Cogburn JN, Gregory SA, Koboldt CM, Perkins WE, Seibert K, Veenhuizen AW, Zhang YY & Isakson PC (1997) Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide (SC-58635, celecoxib). Journal of Medicinal Chemistry 40:1347-1365.
70. Pommier Y, Marchand C & Neamati N (2000) Retroviral integrase inhibitors year 2000: update and perspectives. Antiviral Research 47:139-148.
71. Pommier Y, Pilon A, Bajaj K, Mazumder A & Neamati N (1997) HIV-1 integrase as a target for antiviral drugs. Antiviral Chemistry & Chemotherapy 8:483-503.
72. Rooney CS, Randall WC, Streeter KB, Ziegler C, Cragoc EJ Jr, Schwam H, Michelson SR, Williams HW, Eichler E, Duggan DE, Ulm EH & Noll RM (1983) Inhibitors of glycolic acid oxidase. 4-Substituted 3-hydroxy-1H-pyrrole-2,5- dione derivatives. Journal of Medicinal Chemistry 26:700-714.
73. Sarges R, Howard HR, Koe BK & Weissman A (1989) A novel class of "GABAergic" agents: 1-aryl-3-(aminoalkylidene)oxindoles. Journal of Medicinal Chemistry 32:437-444.
74. Schames JR, Henchman RH, Siegel JS, Sotriffer CA, Ni H & McCammon JA (2004) Discovery of a novel binding trench in HIV integrase. Journal of Medicinal Chemistry 47:1879-1981.
75. Sechi M, Angotzi G, Dallocchio R, Dessi A, Carta F, Sannia L, Mariani A, Fiori S, Sanchez T, Movsessian L, Plasencia C & Neamati N (2004) Design and synthesis of novel dihydroxyindole-2-carboxylic acids as HIV-1 integrase inhibitors. Antiviral Chemistry & Chemotherapy 15:67-81.
76. Sechi M, Derudas M, Dallocchio R, Dessi A, Bacchi A, Sannia L, Carta F, Palomba M, Ragab O, Chan C, Shoemaker R, Sei S, Dayam R & Neamati N (2004) Design and synthesis of novel indole β-diketo acid derivatives as HIV-1 integrase inhibitors. Journal of Medicinal Chemistry 47:5298-5310.
77. 1H-nuclear magnetic resonance. Journal of Heterocyclic Chemistry 40:1097-1102.
78. Sotriffer CA, Ni H & McCammon AJ (2000) HIV-1 Integrase inhibitor interactions at the active site: prediction of binding modes unaffected by crystal packing. Journal of the American Chemical Society 122:6136-6137.
79. Sotriffer CA, Ni H & McCammon AJ (2000) Active site binding modes of HIV-1 Integrase inhibitors. Journal of Medicinal Chemistry 43:4109-4117.
80. Stiles M & Selegue JP (1991) 6-Phenyl-2,4,6-trioxohexanoic acid. Journal of Organic Chemistry 56:4067-4070.
81. Tanaka A, Terasawa T, Hagihara H, Sakuma Y, Ishibe N, Sawada M, Takasugi H & Tanaka H (1998) Inhibitors of acyl-CoA:cholesterol O-acyltransferase. 2. Identification and structure-activity relationships of a novel series of N-alkyl-N-(heteroaryl-substituted benzyl)-N′-arylureas. Journal of Medicinal Chemistry 41:2390-2410.
82. Wai JS, Egbertson MS, Payne LS, Fisher TE, Embrey MW, Tran LO, Melamed JY, Langford HM, Guare JP Jr, Zhuang L, Grey VE, Vacca JP, Holloway MK, Naylor-Olsen AM, Hazuda DJ, Felock PJ, Wolfe AL, Stillmock KA, Schleif WA, Gabryelski LJ & Young SD (2000) 4-Aryl-2,4-dioxobutanoic acid inhibitors of HIV-1 integrase and viral replication in cells. Journal of Medicinal Chemistry 43:4923-4926.
83. Zhiio H, Neamati N, Mazumder A, Sunder S, Pommier Y & Burke TR Jr (1997) Hydrazide-containing inhibitors of HIV-1 integrase. Journal of Medicinal Chemistry 40:1186-1194.